Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer

NCT03362177 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03362177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03362177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2019
Completion date
January 9, 2025
Enrollment
165 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced thrombocytopenia